Document:

Exhibit

EXHIBIT 4.1

DARDEN RESTAURANTS, INC.,

as Company,

and

WELLS FARGO BANK, NATIONAL ASSOCIATION,

as Trustee
    

FIRST SUPPLEMENTAL INDENTURE
Dated as of February 20, 2018
    

This FIRST SUPPLEMENTAL INDENTURE is dated as of February 20, 2018, between DARDEN RESTAURANTS, INC. (the “Company”) and WELLS FARGO BANK, NATIONAL ASSOCIATION (as successor to Wells Fargo Bank Minnesota, National Association, formerly known as Norwest Bank Minnesota, National Association), as Trustee (the “Trustee”).
RECITALS
WHEREAS, the Company and the Trustee entered into an Indenture, dated as of January 1, 1996 (the “Indenture”), pursuant to which the Company issued $300,000,0000 in aggregate principal amount of the 6.800% Senior Notes due 2037 (the “Notes”) pursuant to an officers’ certificate and authentication order dated October 10, 2007 (the “Officers’ Certificate”);
WHEREAS, Section 902 of the Indenture provides that with the consent of the Holders of not less than a majority in aggregate principal amount of the outstanding Notes of each series affected by such supplemental indenture, the Company and the Trustee may enter into an indenture or indentures supplemental to the Indenture for the purpose of adding any provisions to or changing in any manner or eliminating any provisions of the Indenture or of modifying in any manner the rights of the Holders of Notes of such series under the Indenture, except in certain cases that do not apply;
WHEREAS, the Company and the Trustee desire to amend the Indenture and the Officers’ Certificate, which, pursuant to Section 301 of the Indenture, establishes the terms of certain series of the Notes, with the written consent of Holders of at least a majority in aggregate principal amount of the outstanding Notes;
WHEREAS, the Company has made a tender offer to purchase for cash, upon the terms and subject to the conditions set forth in the Offer to Purchase and Consent Solicitation Statement dated January 24, 2018 (the “Offer to Purchase”), the Notes (the “Offer”);
WHEREAS, in connection with the Offer, the Company has proposed certain amendments to the Indenture;
WHEREAS, the Holders of not less than a majority in aggregate principal amount of the Notes have consented to the proposed amendments described in the Offer to Purchase and this Supplemental Indenture pursuant to consent documents obtained prior to the execution hereof;
WHEREAS, the execution of this Supplemental Indenture will not result in a material modification of the Notes for purposes of the Foreign Account Tax Compliance Act; 
WHEREAS, all things necessary to make this Supplemental Indenture when executed by the parties hereto a valid and binding agreement of and supplement to the Indenture have been done and performed;
WHEREAS, the foregoing recitals are made as statements of fact by the Company and not by the Trustee; and
NOW, THEREFORE, to comply with the provisions of the Indenture and in consideration of the above premises, the Company and the Trustee covenant and agree for the benefit of each other and for the equal and proportionate benefit of the respective Holders of the Notes as follows:

1

ARTICLE I

Section 1.1    Unless otherwise defined herein, capitalized terms used herein without definition have the respective meanings given to them in the Indenture.
Section 1.2    This Supplemental Indenture is supplemental to the Indenture and does and shall be deemed to form a part of, and shall be construed in connection with and as part of the Indenture for any and all purposes and shall have effect, so far as practicable, as though all the provisions of the existing Indenture and this Supplemental Indenture were contained in one instrument.  Every Holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby.
Section 1.3    This Supplemental Indenture shall modify the terms of the Notes and, for the avoidance of doubt, does not modify the terms of the other securities issued by the Company pursuant to the Indenture.
ARTICLE II    
Section 2.1    Subject to Section 3.1 below and with respect to the Notes only:
(a)    Sections 501(4), 501(5), 501(8), 704, 801, 1006, 1007, 1008 and 1009 of the Indenture are hereby deleted in their entirety and each of the foregoing is hereby replaced with the following text: “[Intentionally Omitted]”;
(b)    Section 802 is hereby modified by deleting “in accordance with Section 801”;
(c)    Section 1004 is hereby modified by restating such section in its entirety as follows: “The Company shall comply with Section 314(a)(4) of the Trust Indenture Act if required to do so pursuant to the Trust Indenture Act.”;
(d)    Section 1104 is hereby modified by deleting “not less than 30” and replacing such deleted language with “not less than three Business Days”;
(e)    The Indenture is hereby amended by deleting from the Indenture any definitions set forth in Article One for defined terms that are used solely in sections deleted by this Supplemental Indenture.
(f)    The Indenture is hereby amended by deleting from the Indenture any section references to Sections 501(4), 501(5), 501(8), 704, 801, 1006, 1007, 1008 and 1009.
(g)    All references in the Indenture to Sections 802, 1004 and 1104 shall mean references to such sections as amended by this Supplemental Indenture.
(h)    Any of the terms or provisions present in the Indenture or the Notes that relate to any of the provisions of the Indenture amended by this Section 2.1 of this Supplemental Indenture shall also be amended so as to be consistent with the amendments made in this Supplemental Indenture.

2

Section 2.2    Subject to Section 3.1 below and with respect to the Notes only:
(a)    Section A.(8) of the Officers’ Certificate is hereby modified by deleting such section except for the first paragraph thereof.
(b)    All references in the Officers’ Certificate to Section A.(8) shall mean references to such section as amended by this Supplemental Indenture.
(c)    Any of the terms or provisions present in the Officers’ Certificate or the Notes that relate to any of the provisions of the Officers’ Certificate as amended by this Section 2.2 of this Supplemental Indenture shall also be amended so as to be consistent with the amendments made in this Supplemental Indenture.
Section 2.3    Any failure by the Company to comply with the terms of any of the Sections of the Indenture deleted by this Supplemental Indenture (whether before or after the execution of this Supplemental Indenture) shall no longer constitute a default or an Event of Default under the Indenture and shall no longer have any other consequences under the Indenture, in each case with respect to the Notes only.
ARTICLE III    
Section 3.1    The provisions of this Supplemental Indenture shall be effective upon execution and delivery of this instrument by the parties hereto; provided, that Section 2.1 and Section 2.2 of this Supplemental Indenture shall not become operative until the Company accepts for purchase all Notes that were properly tendered and not validly withdrawn pursuant to the Offer.
Section 3.2    Except as specifically modified herein, the Indenture and the Notes are in all respects ratified and confirmed and shall remain in full force and effect in accordance with their terms.  This Supplemental Indenture shall form a part of the Indenture for all purposes, and every Holder of Notes heretofore or hereafter authenticated and delivered under the Indenture shall be bound thereby.  Nothing in this Supplemental Indenture or the Notes, express or implied, shall give to any Person, other than the parties hereto and thereto and their successors hereunder and thereunder and the Holders of the Notes, any benefit of any legal or equitable right, remedy or claim under the Indenture, this Supplemental Indenture or the Notes.
ARTICLE IV    
Section 4.1    Except as otherwise expressly provided herein, no duties, responsibilities or liabilities are assumed, or shall be construed to be assumed, by the Trustee, by reason of this Supplemental Indenture.  This Supplemental Indenture is executed and accepted by the Trustee subject to all the terms and conditions set forth in the Indenture with the same force and effect as if those terms and conditions were repeated in their entirety herein and made applicable to the Trustee with respect hereto.
Section 4.2    THIS SUPPLEMENTAL INDENTURE AND THE NOTES SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
Section 4.3    The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy shall be an original, but all of such executed copies together shall represent the same agreement.

3

Section 4.4    In case any provision of this Supplemental Indenture or in the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
Section 4.5    The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Company.

4

SIGNATURES
IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed, all as of the date first written above.
DARDEN RESTAURANTS, INC.

By:   /s/  William R. White, III    
Name:    William R. White, III
Title:    Senior Vice President and Treasurer

5

WELLS FARGO BANK, NATIONAL ASSOCIATION, (as successor to Wells Fargo Bank Minnesota, National Association, formerly known as Norwest Bank Minnesota, National Association), as Trustee
By  /s/  Stefan Victory    
Name:  Stefan Victory
Title:    Vice President

6EX-4.18

 Exhibit 4.18 
  

			
	

	  	 Barclays Corporate Secretariat
 Level 29

1 Churchill Place

		  	London
	16 February 2017	  	E14 5HP
		
	Sir Ian Cheshire	  	Tel 020 7116 8099
	103 Balham Park Road	  	Fax 020 7116 7785
	London	  	
	SW12 8EB	  	
		  	claire.a.davies@barclays.com

 Dear Sir Ian, 
 I am pleased to confirm the
details of your appointment as an independent non-executive Director of Barclays PLC and Barclays Bank PLC (“the Companies” or “Barclays”) with effect from 3 April 2017. You will also
be appointed as a Director and Chairman of Barclays UK and Europe plc (Barclays UK), the UK ring-fenced bank, with effect from a date to be agreed, for which a separate appointment letter will be issued. Your appointment to the Companies is by
virtue of your impending appointment as the Chairman of Barclays UK. 
  

	1.	Terms of Your Appointment 

 Your initial appointment term will be for three years, with a
further three years agreed with the Chairman, and subject to annual re-election by shareholders (see below). On or after your third and sixth Annual General Meeting (AGM) the Chairman will agree with you
whether it is appropriate for you to continue to serve for up to another three years. In addition, you will have an annual review with the Chairman of your performance as a non-executive Director. The Board
has also adopted a formal system of self-evaluation, which is currently carried out annually. 
 Your appointments are being made by the Directors in
accordance with the Articles of Association of the Companies. As with all of the Directors, you will be required to seek re-election by shareholders at the Barclays PLC AGM each year in accordance with the UK
Corporate Governance Code. 
 Your appointment may be terminated by Barclays on six months’ notice (or immediately on payment of six months fees
in lieu of notice) but would automatically terminate without any entitlement to notice or payment if the Barclays PLC shareholders do not elect or re-elect you whenever you stand for election or re-election, and/or if you are removed from office by the shareholders. If/when your appointment as Chairman of Barclays UK comes to an end the Group Board will consider whether it is appropriate for you to continue
to serve on the Board of the Companies, and reserve the right to terminate the appointment. The Board shall also reserve the right to reconsider your appointment as a Director and therefore to terminate your appointment forthwith without any
entitlement to notice or payment should there be any material change to your personal circumstances that the Board believes may affect your appointment as a Director of Barclays PLC and/or Barclays Bank PLC. A material change shall include, but not
be limited to, the following: 
  

	 	•	 	Where you are appointed to any other company, corporate body or other entity (internal or external to the Barclays Group), or have any other significant commitment which has not been agreed in advance with the Board.

	 	•	 	Where you are guilty of any serious misconduct or any conduct does or is calculated to or is likely to bring any member of the Barclays Group or you into disrepute. 

	 	•	 	Where you become bankrupt (or equivalent in any other jurisdiction) or become the subject of an interim order under the Insolvency Act 1986 or make any arrangements or composition with your creditors. 

  

	 	•	 	Where you are convicted of any criminal offence (other than an offence under any road traffic legislation in the United Kingdom or elsewhere for which a fine or non-custodial
penalty is imposed). 

	 	•	 	Where you become prohibited by law from being a director. 

	 	•	 	Where you are guilty of any material breach or material non-observance of any of the provisions of this letter or its schedules or the rules of any applicable regulatory
authority, or are guilty of any serious negligence in carrying out your duties under this letter. 

	 	•	 	Where you are unable to perform your role due to illness or disability for a period of no fewer than 30 working days in any period of 12 months (provided that the Board will not exercise its rights to terminate your
appointment forthwith in this circumstance without first notifying you and considering any representations you may have). 

 Where such
a material change occurs, you must inform the Chairman as soon as possible. 
 Should you wish to resign your appointment, you are required to give
Barclays not less than six months’ notice. 
 On termination of your appointment you shall: 

 

	 	•	 	at Barclays’ request resign from your office as a Director of Barclays and all offices held by you in any Group company; and 

	 	•	 	deliver to Barclays all documents, records, papers or other company property which may be in your possession or under your control, and which related in any way to the business affairs of Barclays, and you shall not
retain any copies thereof. 

  

	2.	Fees 

 As a non-executive Director you will
receive a fee of £80,000 per annum, payable monthly in arrears by direct credit into your nominated bank account after the deduction of tax and other statutory deductions. This is in addition to any fees payable as the Barclays UK Chairman. In
the event that you hold office for part of the year the fees shall be pro-rated accordingly on the basis of one twelfth for each complete or part month served. £30,000 of your non-executive Director fee, after tax and national insurance, will be used to purchase Barclays PLC shares twice per year, in February/March and July/August, after the announcement of the Companies’ full and
half-year financial results. These shares will be held on your behalf until you leave the Board. Enclosed with this letter is an agreement setting out details in respect of this remuneration in Barclays PLC shares, which you are asked to sign and
return. 
 The fees may be subject to any amendment or qualification as required by any law, regulation or regulatory authority. The Board (with the non-executive Directors abstaining) reviews the level of fees paid to non-executive Directors annually. 

Any reasonable out of pocket expenses that you incur in performing your duties as a Director (travelling expenses in attending Board and Board
Committee meetings etc.) will be reimbursed in accordance with our standard expenses policy. 
  

	3.	Role 

 Attached to this letter is a role profile for
non-executive Directors, which has been agreed by the Board. The Board may change this role profile from time to time and the role profile as amended shall, once notified to you, be deemed to form part of this
letter in place of the document attached. As the Chairman of Barclays UK it is not expected that you will join any Group Board Committees, although as a non-executive Director of Barclays you have a standing
invitation to attend all Group Board Committee meetings. In addition, you may be expected to join ad hoc Group Board Committees as appropriate. 

You will be required to exercise your powers as a Director in accordance with the Company’s policies and procedures and Enterprise Risk Management
Framework. During your appointment you shall diligently perform such duties, responsibilities and functions (whether statutory, fiduciary or common law) as are consistent with your position as a non-executive
Director and the role profile. 
 You will immediately report to the Chairman or to me your own wrongdoing or the wrongdoing or proposed wrongdoing
of any employee or Director of which you become aware. 

  

	4.	Time Commitment 

 The Board normally meets formally 8 times a year, including a 1 1⁄2 day strategy session held each year, and will otherwise meet on an ad-hoc basis as required. Some of the meetings may
be held overseas. The scheduled Board meeting dates for the remainder of the year have been provided to you. Please note that the number of ad-hoc meetings may increase significantly when the Board is required
to address urgent matters as they arise between scheduled meetings. Directors are also expected to attend the Barclays PLC AGM, which is usually in April/May each year, and be available afterwards to meet with and answer questions from shareholders.
You will also be expected to make yourself available during your first year of appointment for the purpose of induction (further details below) and in future years for occasional Board training days. This is in addition to the time commitment
expected of you as Barclays UK Chairman. 
 Directors are expected to attend each meeting of the Board, including those called on an ad-hoc basis to discuss urgent matters, and to set aside sufficient time to consider the papers in respect of those meetings, which for scheduled meetings are normally sent to Directors in the week prior to the
meeting. 
 You will be expected to commit additional time to your role as a non-executive Director as
circumstances require, particularly during periods of increased activity. 
 You have already disclosed to the Board your main existing commitments
outside of the Barclays Group, and you should advise me of any changes to these. Any new commitments which you propose to undertake which could present a potential conflict of interest or which may impact on the time that you are able to devote to
your role at Barclays should be notified to me also so that they can be agreed in advance by the Board and potentially by our regulators. 
  

	5.	Directors Share Qualification 

 Under Barclays PLC’s Articles of Association, you
will be required to hold £500 in nominal value (2,000 ordinary shares of 25p each) of Barclays PLC shares within two months of your appointment (i.e., by June 2017). You must obtain clearance to deal before you acquire these or any Barclays
PLC shares, and I will arrange this on your behalf once you let me know your intentions, if you would also like assistance in arranging to buy these shares, please let me know. 

 

	6.	Price sensitive information and dealing in Barclays’ securities 

 Your attention is
drawn to the requirements under both law and regulation regarding the disclosure of price sensitive information, and in particular to the Market Abuse Regulation, Disclosure Guidance and Transparency Rules of the UK Listing Authority and s52 of the
Criminal justice Act 1993 on insider dealing. You should avoid taking any action that might risk a breach of these requirements. If in doubt please contact me. 

During your period of appointment you are required to comply with the provisions of the Group Securities Dealing Code. A copy of the current Group
Securities Dealing Code adopted by Barclays will be provided to you separately. 
  

	7.	Induction, Values and support 

 We will agree a suitable induction programme with you
shortly, which will enable you to meet some of the key members of our senior management. We will also provide to you further briefing regarding your role, which will include your legal and regulatory duties as a Director and details of procedures
regarding the disclosure of any conflicts of interest, data protection, the control of inside information and for obtaining clearance to deal in Barclays securities. 

The Barclays Values (Respect, Integrity, Service, Excellence and Stewardship) are a central part of everything we do. The Values form a critical part
of how Barclays is changing, as well as our purpose and behaviours. You will be expected to act in accordance with the Values as a non-executive Director of Barclays, and, in particular, to follow our Code of
Conduct (known as the Barclays Way). More information on this, and how we “live” the Values will be available as part of your induction. 

 On-going training and briefings will also be made available,
including any topics that you may request. 
 I and Barclays Corporate Secretariat are available to assist you with both day-to-day and specific matters in your role as a Director of Barclays. Also, should you feel that there may be implications for you personally in carrying out any of the
duties as a Director, you may, with our prior agreement, seek independent advice at Barclays expense. 
  

	8.	Indemnity 

 For the avoidance of doubt, the Boards have confirmed that as a Director of
Barclays PLC and Barclays Bank PLC (and in respect of any directorship that you undertake at the express behest of Barclays) you have the benefit of and are able to rely upon the indemnity contained in Article 147 of the Barclays PLC Articles of
Association and the identical wording in Article 143 of the Barclays Bank PLC Articles of Association, the terms of which are hereby expressly incorporated into this letter of appointment. Copies of the relevant Articles are attached for your ease
of reference. 
 In outline, the effect of the Articles (as restricted by relevant statutory provisions) is to provide an indemnity in respect of
certain liabilities incurred by you in the execution of your duties, provided that the liability does not arise by virtue of your negligence, default, breach of duty or breach of trust in relation to the Bank. The indemnity is of course in addition
to any other protection available to you by virtue of provisions of statute, common law or indeed any specific contract. 
  

	9.	Confidentiality 

 You will appreciate that the business of Barclays PLC and the Barclays
Group is a specialised and competitive business and that during the course of your appointment you will have access to and have an intimate knowledge of the trade secrets and confidential information of Barclays PLC and the Barclays Group. You
further acknowledge that the disclosure of any trade secrets or confidential information to actual or potential competitors of Barclays PLC and/or any Barclays Group Company would place Barclays PLC and/or the Barclays Group at a serious competitive
disadvantage and would do serious damage, financial and/or otherwise, to its or their business and business development and would cause immeasurable harm. 

You must neither during the term of your appointment (except in the proper performance of the duties of your office or with the express written consent
of the Board) nor at any time (without limit) after the termination of your appointment except where disclosure is required by law, by an order of a competent court or by a regulatory body: 

 

	 	•	 	publish, divulge or communicate to any person, company, business entity or other organisation or to the media or any social media; 

	 	•	 	use for your own purposes or for any purposes other than those of Barclays PLC or the Barclays Group; or 

	 	•	 	through any failure to exercise due care and diligence, permit or cause any unauthorised disclosure of 

any Confidential Information. These restrictions shall cease to apply to any information which shall become available to the public generally otherwise
than through any breach by you of the provisions of this letter or other default of yours. 
 All notes, memoranda, records and documents (in
whatever form or media held) that you make during the term of your appointment in performing your duties as non-executive Director will belong to the Barclays Group and will be handed over to Barclays,
together with any copies, promptly from time to time on reasonable request of any Barclays Group Company and at the end of your appointment. 

Nothing in this letter, including but not limited to the provisions on confidentiality above, is intended to or shall prevent you from raising concerns
in line with Barclays’ internal reporting processes or making any disclosure to governmental bodies, law enforcement authorities and/or regulators as permitted or required under applicable law or regulation (including but not limited to a
“protected disclosure” within the meaning of Part 43A (Protected Disclosures) of the Employment Rights Act 1996 and to any protected disclosures made about matters previously disclosed to another recipient). 

  

	10.	Data Privacy 

 Barclays PLC and Barclays Bank PLC shall process your personal information
for administrative and other purposes related to your appointment and the conduct of the business of the Barclays Group (the “Agreed Purposes”). Processing includes obtaining, holding, editing, destroying and disclosing your personal
information to any Barclays Group company and/or any third parties (for example, insurers, banks and new Barclays Group companies following a business transfer or merger) for the Agreed Purposes (“Processing” or “Process”). 

Barclays may transfer your information to any Barclays Group company and/or any third parties (for example, insurers, banks and new Barclays Group
companies following a business transfer or merger) in order to Process your personal information for the Agreed Purposes. 
 You agree to provide
your personal information to Barclays PLC and Barclays Bank PLC and consent to the Processing of that information for the Agreed Purposes. This may include transfers to recipients based in another country to your place of appointment (either within
or outside the European Economic Area). 
 This letter sets out the main terms of your appointment and on acceptance will constitute a contract for services. Would
you please confirm your acceptance of the appointments as set out in this letter by signing the enclosed copy and returning it to me. Please let me know if you would like any further information in connection with these appointments. 

I look forward to working with you. 
  

	
	Yours sincerely
	
	

	Claire Davies
	Company Secretary

 Enclosures: 
  

	 	•	 	Agreement setting out details in respect of the remuneration in Barclays PLC shares, for signature and return; 

	 	•	 	Role profile for non-executive Directors; and 

	 	•	 	Article 147 of the Barclays PLC Articles of Association and Article 143 of the Barclays Bank PLC Articles of Association. 

I agree to the terms and conditions of my appointment as a non-executive Director of Barclays PLC and Barclays Bank PLC as set
out in this letter. 
  

			
	Signed:	 	                         
		
	Name:	 	                        
		
	Date:	 	17/2/17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]